BRPI9917760B8 - método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada - Google Patents

método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada

Info

Publication number
BRPI9917760B8
BRPI9917760B8 BRPI9917760A BR9917760A BRPI9917760B8 BR PI9917760 B8 BRPI9917760 B8 BR PI9917760B8 BR PI9917760 A BRPI9917760 A BR PI9917760A BR 9917760 A BR9917760 A BR 9917760A BR PI9917760 B8 BRPI9917760 B8 BR PI9917760B8
Authority
BR
Brazil
Prior art keywords
uricase
isolating
purified
solution
tetrameric form
Prior art date
Application number
BRPI9917760A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9917760B1 (pt
Inventor
L Williams David
G P Saifer Mark
R Sherman Merry
S Hershfield Michael
J Kelly Susan
Original Assignee
Univ Duke
Mountain View Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Mountain View Pharmaceuticals Inc filed Critical Univ Duke
Publication of BR9917760B1 publication Critical patent/BR9917760B1/pt
Publication of BRPI9917760B8 publication Critical patent/BRPI9917760B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI9917760A 1998-08-06 1999-08-02 método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada BRPI9917760B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13039298A 1998-08-06 1998-08-06
US09/130,132 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (2)

Publication Number Publication Date
BR9917760B1 BR9917760B1 (pt) 2014-11-25
BRPI9917760B8 true BRPI9917760B8 (pt) 2021-05-25

Family

ID=22444494

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9917760A BRPI9917760B8 (pt) 1998-08-06 1999-08-02 método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada
BRPI9912974A BRPI9912974B8 (pt) 1998-08-06 1999-08-02 conjugados de peg-urato oxidase e seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9912974A BRPI9912974B8 (pt) 1998-08-06 1999-08-02 conjugados de peg-urato oxidase e seu uso

Country Status (13)

Country Link
EP (1) EP1100542B1 (enExample)
JP (3) JP5183836B2 (enExample)
KR (2) KR100614212B1 (enExample)
AU (1) AU770014B2 (enExample)
BR (2) BRPI9917760B8 (enExample)
CZ (1) CZ303751B6 (enExample)
HU (2) HU226294B1 (enExample)
IL (3) IL141220A0 (enExample)
NZ (1) NZ509595A (enExample)
PL (2) PL202799B1 (enExample)
RU (3) RU2246318C2 (enExample)
TW (1) TW570981B (enExample)
WO (1) WO2000007629A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1588716E (pt) 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Conjugados de peg-urato oxidase e sua utiliza??o
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
AU766421B2 (en) 1998-08-06 2003-10-16 Duke University Urate oxidase
IL141220A0 (en) * 1998-08-06 2002-03-10 Mountain View Pharmaceuticals Conjugates of peg-urate oxidase and use thereof
AU2006203252B8 (en) * 2000-02-10 2009-06-18 Duke University Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US7455855B2 (en) 2000-04-03 2008-11-25 Santen Pharmaceutical Co., Ltd. Delivering substance and drug delivery system using the same
US7799794B2 (en) 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
DE60229958D1 (de) 2001-06-28 2009-01-02 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
PT1625156E (pt) 2003-05-12 2013-01-09 Affymax Inc Novos péptidos que se fixam ao receptor da eritropoietina
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
WO2006110761A2 (en) * 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
LT3321359T (lt) 2005-04-11 2021-05-10 Horizon Pharma Rheumatology Llc Urato oksidazės variantinės formos ir jų panaudojimas
EP1883405A4 (en) 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP5033177B2 (ja) * 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
JP4890132B2 (ja) * 2006-07-20 2012-03-07 東洋紡績株式会社 ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ
RU2382048C1 (ru) * 2008-12-25 2010-02-20 Общество С Ограниченной Ответственностью "Фармапарк" Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием
PL398781A1 (pl) 2009-06-25 2012-11-19 Savient Pharmaceuticals, Inc. Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy
CN103298466B (zh) 2010-09-10 2015-11-25 武田制药美国有限公司 茶碱和非布索坦的联合治疗方法
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
WO2013151638A1 (en) 2012-04-06 2013-10-10 Indus Pharmaceuticals, Inc. Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
MX2021005697A (es) 2013-05-03 2021-07-07 Selecta Biosciences Inc Suministro de inmunosupresores que tienen una vida efectiva especificada, farmacodinamica y antigeno para la induccion de tolerancia inmunitaria.
MX2017014547A (es) * 2015-05-15 2018-03-15 Medimmune Llc Secuencias de uricasa mejoradas y metodos de tratamiento.
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
CN112980808B (zh) * 2019-12-12 2024-10-29 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
KR20230110281A (ko) 2020-11-03 2023-07-21 프로탈릭스 리미티드 변형된 유리카제(uricase) 및 이의 용도
CN114438047B (zh) * 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CA3211023A1 (en) 2021-02-10 2022-08-18 Oriental Yeast Co., Ltd. Uricase activator and uric acid measurement reagent
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1529675A (fr) * 1967-03-29 1968-06-21 Applic Biochimiques Soc Et Urate oxydase à haute activité et sa préparation
US3616231A (en) * 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6031472B2 (ja) * 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
JPS55135590A (en) * 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
AU766421B2 (en) * 1998-08-06 2003-10-16 Duke University Urate oxidase
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
IL141220A0 (en) * 1998-08-06 2002-03-10 Mountain View Pharmaceuticals Conjugates of peg-urate oxidase and use thereof

Also Published As

Publication number Publication date
KR20010072287A (ko) 2001-07-31
KR20040088585A (ko) 2004-10-16
RU2246318C2 (ru) 2005-02-20
PL220873B1 (pl) 2016-01-29
EP1100542B1 (en) 2005-06-22
TW570981B (en) 2004-01-11
IL183948A (en) 2010-11-30
JP2009254376A (ja) 2009-11-05
WO2000007629A2 (en) 2000-02-17
AU770014B2 (en) 2004-02-12
RU2349341C2 (ru) 2009-03-20
RU2278680C2 (ru) 2006-06-27
BR9917760B1 (pt) 2014-11-25
JP2002522399A (ja) 2002-07-23
AU5251599A (en) 2000-02-28
JP5290901B2 (ja) 2013-09-18
RU2006107111A (ru) 2007-09-20
HUP0103003A3 (en) 2006-04-28
PL202799B1 (pl) 2009-07-31
HU228916B1 (en) 2013-06-28
WO2000007629A3 (en) 2000-06-08
IL141220A0 (en) 2002-03-10
IL141220A (en) 2007-09-20
EP1100542A2 (en) 2001-05-23
KR100614212B1 (ko) 2006-08-21
RU2004104953A (ru) 2005-07-27
PL383331A1 (enExample) 2002-01-28
BRPI9912974B1 (pt) 2015-08-25
IL183948A0 (en) 2007-10-31
JP2013039139A (ja) 2013-02-28
CZ2001317A3 (cs) 2001-07-11
NZ509595A (en) 2004-02-27
JP5291235B2 (ja) 2013-09-18
KR100488848B1 (ko) 2005-05-11
CZ303751B6 (cs) 2013-04-24
HU226294B1 (en) 2008-08-28
JP5183836B2 (ja) 2013-04-17
HUP0103003A2 (hu) 2001-11-28
BRPI9912974B8 (pt) 2021-05-25
PL346224A1 (en) 2002-01-28
BR9912974A (pt) 2001-05-08

Similar Documents

Publication Publication Date Title
BRPI9917760B8 (pt) método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada
AU5624699A (en) Use of 5ht-6 antagonists
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
MXPA05011223A (es) Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
IL183953A0 (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical, or stored blood
BR9910251A (pt) Estimulação hematopoiética
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
BR0008176A (pt) Derivados anti-convulsivantes úteis no tratamento de cefaléias em cacho
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
DE69943205D1 (de) Peg-uricase Konjugate und Verwendung davon
NZ502610A (en) Use of lactobacillus for reduction of the fibrinogen level in blood
SG161247A1 (en) Variant forms of urate oxidase and use thereof
WO2001097829A3 (en) Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
NO990522L (no) Anvendelse av <beta>-ark mimetika som protease- og kinaseinhibatorer av transkripsjonsfaktorer
BR0311161A (pt) Método de tratamento de diabetes
WO2002018361A3 (en) Compounds having activity as inhibitors of cytochrome p450rai
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
WO2005056040A3 (en) Systems and methods related to degradation of uremic toxins
WO2004069781A3 (en) 7-(3,5-diisopropylphenyl) heptatrienoic acid derivatives having serum glucose reducing activity
WO2001007644A3 (en) Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
MXPA03006742A (es) Uso de buprenorfina para la terapia de la incontinencia urinaria.
BR0303367A (pt) Células de mycobacterium w, veìculo farmaceuticamente aceitável, preservativo, ruptura de mycobacterium w, extração de solvente, enzimas usadas para a extração enzimática de células de mycobacterium w, adjuvante, composição farmacêutica, tensoativo, e, concentração de tensoativo do processo de fabricar uma composição farmacêutica para a administração de tuberculose
WO2004041071A3 (en) Compositions, systems, and methods for focusing a cell-mediated immune response

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)

Free format text: EXTINCAO DEFINITIVA - ART. 78 INCISO IV DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/11/2014, OBSERVADAS AS CONDICOES LEGAIS.

B24E Patent annual fee: resolution cancelled

Free format text: REFERENTE AO DESPACHO 24.8 PUBLICADO NA RPI 2289 DE 18/11/2014.

B15K Others concerning applications: alteration of classification

Ipc: C12N 9/06 (2006.01), A61K 47/60 (2017.0

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/08/2019